Orthofix seeks to understand bone growth technology:
This article was originally published in Clinica
Orthofix International is funding a trial that will seek to define the molecular and cellular mechanisms of action of its PEMF (pulsed electromagnetic field) technology in stimulating bone growth. The Huntersville, North Carolina firm has given around $2 million to the Orthopaedic Research and Education Foundation as part of a four-year collaboration for the study, which will be conducted at the Cleveland Clinic Foundation, in Ohio. Orthofix plans to expand application of the PEMF platform from bone growth stimulation to other diseases and injuries.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.